What Causes Facial Nerve Palsy?
Discussion
Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma
MONDAY, May 20, 2019 -- For patients with mild asthma with a low sputum eosinophil level, outcomes do not differ significantly for mometasone or tiotropium versus placebo; and budesonide-formoterol is superior to albuterol for prevention of asthma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 20, 2019 Category: Pharmaceuticals Source Type: news
Albuterol Before Tonsillectomy Protects Against Respiratory Problems Albuterol Before Tonsillectomy Protects Against Respiratory Problems
Preoperative inhaled albuterol can help protect against perioperative respiratory adverse events in young children undergoing anesthesia for tonsillectomy, according to data from the Australian REACT trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Endo Begins Shipment of Authorized Generic Version of PROVENTIL(R) (albuterol sulfate) HFA Inhalation Aerosol in the United States
DUBLIN, April 5, 2019 -- (Healthcare Sales & Marketing Network) -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical (Par), has begun shipping an authorized generic version of Merck's PROVENTIL&r... Biopharmaceuticals, Generics Endo International, Par Pharmaceutical, PROVENTIL, albuterol sulfate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2019 Category: Pharmaceuticals Source Type: news
albuterol (Ventolin, Proventil)
Title: albuterol (Ventolin, Proventil)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/26/2019 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - March 26, 2019 Category: Respiratory Medicine Source Type: news
albuterol and ipratropium inhaler (Combivent Respimat)
Title: albuterol and ipratropium inhaler (Combivent Respimat)Category: MedicationsCreated: 4/4/1999 12:00:00 AMLast Editorial Review: 3/21/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - March 21, 2019 Category: Drugs & Pharmacology Source Type: news
Proair Digihaler (Albuterol Sulfate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 16, 2019 Category: Drugs & Pharmacology Source Type: news
FDA approves Teva's digital inhaler for asthma & COPD patients
The Food and Drug Administration approved Teva Pharmaceutical Industries Ltd.'s ProAir Digihaler, a device the company describes as "the first and only digital inhaler with built-in sensors that detect when the inhaler is used and measure inhalation flow."
The ProAir Digihaler was approved for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm in patients aged 4 years and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 27, 2018 Category: Biotechnology Authors: John George Source Type: news
FDA approves Teva ’s digital COPD, asthma inhaler
Teva (NYSE:TEVA) said this week that the FDA approved its ProAir Digihaler device – a digital inhaler that uses sensors to connect to a companion mobile app for people with asthma and chronic obstructive pulmonary disease.
The company’s device features built-in sensors that can measure inspiratory flow and detect when the inhaler is used. After the data is sent to a mobile app, the user can review historical data and share it with their healthcare professionals.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Teva’s digital COPD, asthma inhaler appeared first on MassDevice. ...
Source: Mass Device - December 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Teva Pharmaceuticals Source Type: news
FDA Approves First Digital Inhaler With Tracking App FDA Approves First Digital Inhaler With Tracking App
The ProAir Digihaler (albuterol sulfate) has a sensor that connects to a companion mobile application that can monitor use.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors
JERUSALEM--(BUSINESS WIRE)--Dec 21, 2018--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir® Digihaler™ (albuterol sulfate 117 mcg) inhalation... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 21, 2018 Category: Drugs & Pharmacology Source Type: news
How Digital Health Technologies Could Make a Difference
Digital technologies are already changing healthcare. Adherium’s Hailie sensor, for instance, which transforms a traditional inhaler into a smart device, is already reportedly demonstrating reductions in emergency hospital visits. Mark Jones, vice president of R&D for Adherium, will share the story behind Hailie at BIOMEDevice San Jose’s Digital Health Product Spotlight on December 6. He’ll be joined by other digital technology trailblazers Angela McIntyre, executive director of eWear (Stanford Wearable Electronics Initiative); Chalisa Prarasri, CEO & co-founder...
Source: MDDI - November 15, 2018 Category: Medical Devices Authors: Daphne Allen Tags: BIOMEDevice San Jose Digital Health Source Type: news
Managing the Toxic Chemical Release that Occurs During a Crush Injury
Conclusion
Remember, crush injuries are a different form of trauma that require a very different mindset and approach to patient care. Local physiologic deterioration can begin very quickly, but systemic effects aren’t seen until the external pressure on the extremity or body part is released.
The presentation of crush injuries can also be very clandestine, as in automobile accidents, due to local or central sensory neurological interruption and damage.
Therefore, it’s essential to insist upon earliest possible access to the patient to assess the possible/probable extent of any crush injury and prepare/monitor the pati...
Source: JEMS Special Topics - October 22, 2018 Category: Emergency Medicine Authors: Andrew Parrish, MD, EMT-P Tags: Trauma Exclusive Articles Source Type: news
For HFpEF, Better Heart-Lung Connection with Albuterol
(MedPage Today) -- Beta-agonist linked to improved exercise hemodynamic measures (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2018 Category: Cardiology Source Type: news
Adherium receives additional FDA clearance for OTC sale of inhaler sensors in the US
Connected inhaler sensor maker Adherium has received 510(k) clearance for US over-the-counter sales of its Hailie sensor, formerly known as Smartinhaler. Specifically, individual versions of the device have been cleared for use with the asthma inhalers ProAir HFA, Ventolin HFA, and Flovent HFA. “This latest clearance kicks off our official entry into the US consumer market, giving the tens of millions of US patients suffering from chronic respiratory conditions their own sidekick for asthma and COPD,” Arik Anderson, CEO of Adherium, said in a statement. (Source: mobihealthnews)
Source: mobihealthnews - July 27, 2018 Category: Information Technology Source Type: news
